Today’s consumers have unprecedented access, choice, buying power brought on by mobile devices, social networks, and digital media. Join us as we expose the stage-by-stage multitudes of influences that impact how consumers experience today’s real-time decision journey and uncover the many “whys” surrounding choice and behavior.
Today’s patients are active stakeholders in their healthcare journey and more digitally-aware than ever. We expose the stage-by-stage multitudes of influences that impact how patients experience disease progression and uncover the many “whys” surrounding choice and behavior.
Check out Gil's latest interview on the parallels between military and corporate intelligence, and why "there is no magic 8 ball when it comes to analytics solutions."
Former Vice President, Global Commercial Services for Procter & Gamble sees the company as the system of record for detecting “signals from the noise” from today’s data overload.
Today we are proud to announce that Bryan Painter and John Seaner have joined Signals executive team, adding the sales and marketing expertise to drive our rapid growth and expansion! Bryan Painter will lead global sales and field operations, and John will oversee global marketing, product strategy and business development efforts.
Signals Analytics is proud to announce that we work with over 60 leading global brands to drive product success. Our military intelligence-inspired machine learning and predictive analytics platform detects signals from the world’s unstructured and unconnected data to enable optimal commercial decisions. Learn more about our clients, establishment of our NYC headquarters, and growth plans in our latest release here!
We are proud to announce our rank of 21st on the 2016 Deloitte Technology Fast 50™ list for our 273% growth rate. Signals Analytics’ spectacular growth is attributable to the company’s ability to turn the world's unstructured data into actionable insights to propel innovation, enhance customer experience and accelerate commercial decision-making.
CRO Kobi Gershoni and EVP of Sciences Alexandra Eberhard discuss how the microbiome will lead a revolution in the consumerization of personalized medicine and diet in today's TechCrunch network. Check it out!CRO Kobi Gershoni and EVP of Sciences Alexandra Eberhard discuss how the microbiome will lead a revolution in the consumerization of personalized medicine and diet in today's TechCrunch network. Check it out!
Beverage World featuring Signals' Co-founder and CEO Gil Sadeh's byline on beverage innovation has run their June Issue! Check out Gil Sadeh's "Recipe for a hit: big data: The key to the next winning beverage is hidden in open-source data".
We have closed a new funding round led by Qumra Capital, an Israeli late-stage venture fund focused on investments in technology companies’ rapid growth, for $10 million. The new capital will be used to accelerate Signals' global expansion and recruitment efforts in the US, Europe, and Israel. Qumra Managing Partner Boaz Dinte will join Signals' Board of Directors.
We're very excited to be recognized as a 2016 Cool Vendor in R&D for Manufacturers by Gartner. For us, we believe it's the validation that decision-makers in R&D, Marketing, and Product Development crave new insights for their decision making process – and our goal is to provide those insights based on the data that's out there. We want to arm our users, who face heavy decisions every day, with the evidence – to make those decisions with more clarity and confidence, and support innovation, growth and success
The big data to intelligence project [led by Signals] told us that patients wanted a better taste... the next step was to implement the insights for all our new drugs. The impact of the project has been widespread," says Heresh Rezavandi, UCB's ecosystem strategic intelligence lead. See today's article in Pharma Times on how Signals is helping UCB and other companies find innovative approaches to go "Beyond the Pill."
Signals' Dr. Alexandra V. Eberhard, General Manager of Signals Europe and EVP of Sciences at Signals will be speaking on the first day of the conference and hosting an exhibit. The presentation will focus on reading the signals from external data to bring patients value.
UCB's Director of Intelligence Heresh Revazandi will be presenting at Pharma CI the impact of Signals' findings in reshaping UCB's approach to innovation beyond-the-pill and patient experience. The presentation will cover Signals insights on packaging, reformulation, and analysis on patient segmentation and journey.
At IMCAS, the world's largest cosmetics exhibition fair, Signals' Dr. Alexandra V. Eberhard will be co-presenting with Thierry Oddos of J&J on the shift from professional to home-use in beauty products and devices. Signals and J&J have partnered on over 80 engagements covering product and technology trends spanning the entire space of healthcare.
Signals has been ranked 34th on the 2015 Deloitte Technology Fast50™ List. CEO Gil Sadeh comments: “Signals is gratified to receive this recognition of our growth, which comes as a direct result of our clients’ endorsement of our insight and analytics capabilities.” Deloitte cites Signals Group’s 179% growth rate for inclusion on the list.
“Our goal was to harness the power of external big data to produce high-level business insights that are immediately actionable for business leaders," says Signals CEO Gil Sadeh. "With support from Sequoia, Signals will continue to work with the greatest minds in data and computer science to develop a wider analytic portfolio designed for the Board room.”
Termed the “app store for innovation” by Forbes contributor Gil Press, Signals was featured last week empowering data-driven product managers looking to make smarter, faster around developing and launching new products. Interviewing Signals' CEO Gil Sadeh, Press focused on how Signals' serves product managers, who have traditionally been very data-driven, with a new approach that allows them to make meaning out of the explosion of new data that is found on the open web.
Check out TDWI's Business Intelligence Journal article "4 Big Data Truths" by Signals' Co-founder and Chief Research Officer Kobi Gershoni. Read on to see how he explains four distinct pillars of a successful big data strategy for decision makers in new product development.
Experience a new workshop over a free breakfast for pharma professionals on how to actually use intelligence from big data to answer key business challenges you face every day. Join Signals’ Dr. Shlomi Madar, Mariel Ackerman M.Sc. and other leading pharma professionals as we share with you how intelligence from big data has the potential to revolutionize the market research and R&D process, and give you useful tools that you can bring back to your organization immediately.
Unwind after a long day at FEI with Signals’ CEO Gil Sadeh and leading big data and innovation experts Frank Moss and Thomas Thurston. Join us for drinks, snacks and a stimulating panel featuring some of the leading minds in making big data analytics meaningful for innovation and product teams.
Come see Signals' very own Executive Vice President of Life Sciences, Dr. Alexandra V. Eberhard speak April 21-22 in Berlin at ENG's Innovation Fusion 2015: NPD Technology Excellence for Chem & FMCG. Bringing together leading experts in R&D and innovation from both the specialty chemical as well as the fast-moving consumer goods sectors.
Signals Analytics is participating in the American Food Technology & Innovation Summit April 14-15 in Chicago!
Check out Signals' Co-founder and CEO Gil Sadeh's article "How Data Built Your New Favorite Beverage" featured in Business Solutions Magazine. "It’s when companies turn their attention outward to the masses of unstructured data that they can understand not just what already exists, but what ought to be".
Signals' CEO Gil Sadeh graces the front page of VentureBeat today sharing three ways that open data on the web is revolutionizing the new product development process for companies. See how using open data reveals what people really need and don’t have on one end, and what technologies can make a meaningful impact on the other — here lies the sweet spot where the next breakthrough product is waiting.